| 12485157 |
Method of treating COVID-19 |
Robert Steven Kania, Dafydd Rhys Owen, Markus Pettersson, Matthew Forrest Sammons, Jamison Bryce Tuttle |
2025-12-02 |
|
| 12421241 |
Substituted pyridines as PARP1 inhibitors |
Porino Jinjo VA, Joseph Robert Pinchman, Qing Dong, Stephen W. Kaldor |
2025-09-23 |
|
| 12384780 |
PARP1 inhibitors and uses thereof |
Qing Dong, Stephen W. Kaldor, Joseph Robert Pinchman, Lynnie Trzoss, Porino Jinjo VA |
2025-08-12 |
|
| 12139462 |
Pyridinone MK2 inhibitors and uses thereof |
Lynnie Trzoss, Qing Dong, Stephen W. Kaldor |
2024-11-12 |
|
| 12006322 |
Substituted pyridines as PARP1 inhibitors |
Porino Jinjo VA, Joseph Robert Pinchman, Qing Dong, Stephen W. Kaldor |
2024-06-11 |
|
| 11987574 |
MK2 inhibitors and uses thereof |
Lynnie Trzoss, Qing Dong, Stephen W. Kaldor |
2024-05-21 |
|
| 11939329 |
PARP1 inhibitors and uses thereof |
Porino Jinjo VA, Joseph Robert Pinchman, Lynnie Trzoss, Qing Dong, Stephen W. Kaldor |
2024-03-26 |
|
| 11926642 |
Compounds and methods for the treatment of COVID-19 |
Robert Steven Kania, Padmavani Bezawada, Emma Louise Hawking, Rohit Jaini, Samir Kulkarni +11 more |
2024-03-12 |
$461,539,000 |
| 11802128 |
Azetidine and pyrrolidine PARP1 inhibitors and uses thereof |
Qing Dong, Stephen W. Kaldor, Lynnie Trzoss, Porino Jinjo VA |
2023-10-31 |
|
| 11795173 |
Substituted pyridines as PARP1 inhibitors |
Porino Jinjo VA, Joseph Robert Pinchman, Qing Dong, Stephen W. Kaldor |
2023-10-24 |
|
| 11773082 |
CDK2 inhibitors |
Douglas C. Behenna, Kevin Daniel Freeman-Cook, Asako Nagata, Sacha Ninkovic, Scott Channing Sutton |
2023-10-03 |
$498,891,000 |
| 11718603 |
CDK2 inhibitors |
Douglas C. Behenna, Kevin Daniel Freeman-Cook, Asako Nagata, Sacha Ninkovic, Scott Channing Sutton |
2023-08-08 |
$554,183,000 |
| 11685719 |
Pyridinone MK2 inhibitors and uses thereof |
Lynnie Trzoss, Qing Dong, Stephen W. Kaldor |
2023-06-27 |
|
| 11680056 |
MK2 inhibitors and uses thereof |
Lynnie Trzoss, Qing Dong, Stephen W. Kaldor |
2023-06-20 |
|
| 11396512 |
CDK2/4/6 inhibitors |
Douglas C. Behenna, Ping Chen, Kevin Daniel Freeman-Cook, Mehran Jalaie, Asako Nagata +5 more |
2022-07-26 |
$1,138,814,000 |
| 11014911 |
CDK2 inhibitors |
Douglas C. Behenna, Kevin Daniel Freeman-Cook, Asako Nagata, Sacha Ninkovic, Scott Channing Sutton |
2021-05-25 |
$425,301,000 |
| 10800783 |
CDK2/4/6 inhibitors |
Douglas C. Behenna, Ping Chen, Kevin Daniel Freeman-Cook, Mehran Jalaie, Asako Nagata +5 more |
2020-10-13 |
$1,301,883,000 |
| 10676471 |
Cycloalkyl-linked diheterocycle derivatives |
Aaron Craig Burns, Michael Raymond Collins, Samantha Elizabeth Greasley, Peter Qinhua Huang, Robert Steven Kania +6 more |
2020-06-09 |
$602,135,000 |
| 10233188 |
CDK2/4/6 inhibitors |
Kevin Daniel Freeman-Cook, Asako Nagata, Sacha Ninkovic |
2019-03-19 |
$456,507,000 |
| 10125130 |
Cycloalkyl-linked diheterocycle derivatives |
Aaron Craig Burns, Michael Raymond Collins, Samantha Elizabeth Greasley, Peter Qinhua Huang, Robert Steven Kania +6 more |
2018-11-13 |
$263,923,000 |
| 9133215 |
Macrocyclic derivatives for the treatment of diseases |
Simon Bailey, Benjamin Joseph Burke, Michael Raymond Collins, Jingrong Jean Cui, Judith Gail Deal +9 more |
2015-09-15 |
$290,120,000 |
| 8680111 |
Macrocyclic derivatives for the treatment of diseases |
Simon Bailey, Benjamin Joseph Burke, Michael Raymond Collins, Jingrong Jean Cui, Judith Gail Deal +9 more |
2014-03-25 |
$751,869,000 |
| 7250418 |
Compounds as CRF1 receptor antagonists |
Jeffrey Corbett, Michael Ennis, Kristine E. Frank, Jian-Min Fu, Patrick Robert Verhoest |
2007-07-31 |
$138,124,000 |
| 7087617 |
Substituted pyrimidine derivatives |
Jeffrey Corbett, Michael Ennis, Kristine E. Frank, Jian-Min Fu, Patrick Robert Verhoest |
2006-08-08 |
$496,056,000 |
| 7041672 |
Substituted aryl 1, 4-pyrazine derivatives |
Patrick Robert Verhoest, Jeffrey Corbett, Michael Ennis, Kristine E. Frank, Jian-Min Fu |
2006-05-09 |
$303,797,000 |
